Research ArticleArticle
Precision, Reliability, and Responsiveness of a Novel Automated Quantification Tool for Cartilage Thickness: Data from the Osteoarthritis Initiative
Michael Antony Bowes, Gwenael Alain Guillard, Graham Richard Vincent, Alan Donald Brett, Christopher Brian Hartley Wolstenholme and Philip Gerard Conaghan
The Journal of Rheumatology April 2019, jrheum.180541; DOI: https://doi.org/10.3899/jrheum.180541
Michael Antony Bowes
From Imorphics Ltd., Manchester; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK. This study was supported by internal funding. Scientific and financial support for the US Foundation for the National Institutes of Health (FNIH) Osteoarthritis Biomarkers Consortium and the study are made possible through grants and direct contributions provided by AbbVie, Amgen, Arthritis Foundation, Bioiberica S.A., DePuy Mitek, Flexion Therapeutics, GlaxoSmithKline, Merck Serono, Rottapharm Madaus, Sanofi, and Stryker, The Pivotal Osteoarthritis Initiative (OAI) Magnetic Resonance Imaging Analyses (POMA) Study, NIH HHSN2682010000. The OAI is a public–private partnership comprising 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the NIH, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corp., GlaxoSmithKline, and Pfizer Inc. Private sector funding for the Consortium and OAI is managed by the FNIH. This manuscript was prepared using an OAI public use dataset and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. PGC is supported in part by the NIHR infrastructure at Leeds. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. PGC has undertaken consultancies or speaker bureaus for AbbVie, Flexion, Novartis, and Pfizer. MAB, GAG, GRV, CBW, and ADB are employees of Imorphics Ltd., a wholly owned subsidiary of Stryker Corp. M.A. Bowes, PhD, Imorphics Ltd.; G.A. Guillard, PhD, Imorphics Ltd.; G.R. Vincent, PhD, Imorphics Ltd.; A.D. Brett, PhD, Imorphics Ltd.; C.B. Wolstenholme, BSc, Imorphics Ltd.; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre. Address correspondence to Prof. P.G. Conaghan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. E-mail: p.conaghan@leeds.ac.uk. Accepted for publication March 26, 2019.
Gwenael Alain Guillard
From Imorphics Ltd., Manchester; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK. This study was supported by internal funding. Scientific and financial support for the US Foundation for the National Institutes of Health (FNIH) Osteoarthritis Biomarkers Consortium and the study are made possible through grants and direct contributions provided by AbbVie, Amgen, Arthritis Foundation, Bioiberica S.A., DePuy Mitek, Flexion Therapeutics, GlaxoSmithKline, Merck Serono, Rottapharm Madaus, Sanofi, and Stryker, The Pivotal Osteoarthritis Initiative (OAI) Magnetic Resonance Imaging Analyses (POMA) Study, NIH HHSN2682010000. The OAI is a public–private partnership comprising 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the NIH, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corp., GlaxoSmithKline, and Pfizer Inc. Private sector funding for the Consortium and OAI is managed by the FNIH. This manuscript was prepared using an OAI public use dataset and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. PGC is supported in part by the NIHR infrastructure at Leeds. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. PGC has undertaken consultancies or speaker bureaus for AbbVie, Flexion, Novartis, and Pfizer. MAB, GAG, GRV, CBW, and ADB are employees of Imorphics Ltd., a wholly owned subsidiary of Stryker Corp. M.A. Bowes, PhD, Imorphics Ltd.; G.A. Guillard, PhD, Imorphics Ltd.; G.R. Vincent, PhD, Imorphics Ltd.; A.D. Brett, PhD, Imorphics Ltd.; C.B. Wolstenholme, BSc, Imorphics Ltd.; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre. Address correspondence to Prof. P.G. Conaghan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. E-mail: p.conaghan@leeds.ac.uk. Accepted for publication March 26, 2019.
Graham Richard Vincent
From Imorphics Ltd., Manchester; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK. This study was supported by internal funding. Scientific and financial support for the US Foundation for the National Institutes of Health (FNIH) Osteoarthritis Biomarkers Consortium and the study are made possible through grants and direct contributions provided by AbbVie, Amgen, Arthritis Foundation, Bioiberica S.A., DePuy Mitek, Flexion Therapeutics, GlaxoSmithKline, Merck Serono, Rottapharm Madaus, Sanofi, and Stryker, The Pivotal Osteoarthritis Initiative (OAI) Magnetic Resonance Imaging Analyses (POMA) Study, NIH HHSN2682010000. The OAI is a public–private partnership comprising 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the NIH, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corp., GlaxoSmithKline, and Pfizer Inc. Private sector funding for the Consortium and OAI is managed by the FNIH. This manuscript was prepared using an OAI public use dataset and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. PGC is supported in part by the NIHR infrastructure at Leeds. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. PGC has undertaken consultancies or speaker bureaus for AbbVie, Flexion, Novartis, and Pfizer. MAB, GAG, GRV, CBW, and ADB are employees of Imorphics Ltd., a wholly owned subsidiary of Stryker Corp. M.A. Bowes, PhD, Imorphics Ltd.; G.A. Guillard, PhD, Imorphics Ltd.; G.R. Vincent, PhD, Imorphics Ltd.; A.D. Brett, PhD, Imorphics Ltd.; C.B. Wolstenholme, BSc, Imorphics Ltd.; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre. Address correspondence to Prof. P.G. Conaghan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. E-mail: p.conaghan@leeds.ac.uk. Accepted for publication March 26, 2019.
Alan Donald Brett
From Imorphics Ltd., Manchester; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK. This study was supported by internal funding. Scientific and financial support for the US Foundation for the National Institutes of Health (FNIH) Osteoarthritis Biomarkers Consortium and the study are made possible through grants and direct contributions provided by AbbVie, Amgen, Arthritis Foundation, Bioiberica S.A., DePuy Mitek, Flexion Therapeutics, GlaxoSmithKline, Merck Serono, Rottapharm Madaus, Sanofi, and Stryker, The Pivotal Osteoarthritis Initiative (OAI) Magnetic Resonance Imaging Analyses (POMA) Study, NIH HHSN2682010000. The OAI is a public–private partnership comprising 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the NIH, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corp., GlaxoSmithKline, and Pfizer Inc. Private sector funding for the Consortium and OAI is managed by the FNIH. This manuscript was prepared using an OAI public use dataset and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. PGC is supported in part by the NIHR infrastructure at Leeds. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. PGC has undertaken consultancies or speaker bureaus for AbbVie, Flexion, Novartis, and Pfizer. MAB, GAG, GRV, CBW, and ADB are employees of Imorphics Ltd., a wholly owned subsidiary of Stryker Corp. M.A. Bowes, PhD, Imorphics Ltd.; G.A. Guillard, PhD, Imorphics Ltd.; G.R. Vincent, PhD, Imorphics Ltd.; A.D. Brett, PhD, Imorphics Ltd.; C.B. Wolstenholme, BSc, Imorphics Ltd.; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre. Address correspondence to Prof. P.G. Conaghan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. E-mail: p.conaghan@leeds.ac.uk. Accepted for publication March 26, 2019.
Christopher Brian Hartley Wolstenholme
From Imorphics Ltd., Manchester; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK. This study was supported by internal funding. Scientific and financial support for the US Foundation for the National Institutes of Health (FNIH) Osteoarthritis Biomarkers Consortium and the study are made possible through grants and direct contributions provided by AbbVie, Amgen, Arthritis Foundation, Bioiberica S.A., DePuy Mitek, Flexion Therapeutics, GlaxoSmithKline, Merck Serono, Rottapharm Madaus, Sanofi, and Stryker, The Pivotal Osteoarthritis Initiative (OAI) Magnetic Resonance Imaging Analyses (POMA) Study, NIH HHSN2682010000. The OAI is a public–private partnership comprising 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the NIH, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corp., GlaxoSmithKline, and Pfizer Inc. Private sector funding for the Consortium and OAI is managed by the FNIH. This manuscript was prepared using an OAI public use dataset and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. PGC is supported in part by the NIHR infrastructure at Leeds. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. PGC has undertaken consultancies or speaker bureaus for AbbVie, Flexion, Novartis, and Pfizer. MAB, GAG, GRV, CBW, and ADB are employees of Imorphics Ltd., a wholly owned subsidiary of Stryker Corp. M.A. Bowes, PhD, Imorphics Ltd.; G.A. Guillard, PhD, Imorphics Ltd.; G.R. Vincent, PhD, Imorphics Ltd.; A.D. Brett, PhD, Imorphics Ltd.; C.B. Wolstenholme, BSc, Imorphics Ltd.; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre. Address correspondence to Prof. P.G. Conaghan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. E-mail: p.conaghan@leeds.ac.uk. Accepted for publication March 26, 2019.
Philip Gerard Conaghan
From Imorphics Ltd., Manchester; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK. This study was supported by internal funding. Scientific and financial support for the US Foundation for the National Institutes of Health (FNIH) Osteoarthritis Biomarkers Consortium and the study are made possible through grants and direct contributions provided by AbbVie, Amgen, Arthritis Foundation, Bioiberica S.A., DePuy Mitek, Flexion Therapeutics, GlaxoSmithKline, Merck Serono, Rottapharm Madaus, Sanofi, and Stryker, The Pivotal Osteoarthritis Initiative (OAI) Magnetic Resonance Imaging Analyses (POMA) Study, NIH HHSN2682010000. The OAI is a public–private partnership comprising 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the NIH, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corp., GlaxoSmithKline, and Pfizer Inc. Private sector funding for the Consortium and OAI is managed by the FNIH. This manuscript was prepared using an OAI public use dataset and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. PGC is supported in part by the NIHR infrastructure at Leeds. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health. PGC has undertaken consultancies or speaker bureaus for AbbVie, Flexion, Novartis, and Pfizer. MAB, GAG, GRV, CBW, and ADB are employees of Imorphics Ltd., a wholly owned subsidiary of Stryker Corp. M.A. Bowes, PhD, Imorphics Ltd.; G.A. Guillard, PhD, Imorphics Ltd.; G.R. Vincent, PhD, Imorphics Ltd.; A.D. Brett, PhD, Imorphics Ltd.; C.B. Wolstenholme, BSc, Imorphics Ltd.; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre. Address correspondence to Prof. P.G. Conaghan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. E-mail: p.conaghan@leeds.ac.uk. Accepted for publication March 26, 2019.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 3
1 Mar 2024
Precision, Reliability, and Responsiveness of a Novel Automated Quantification Tool for Cartilage Thickness: Data from the Osteoarthritis Initiative
Michael Antony Bowes, Gwenael Alain Guillard, Graham Richard Vincent, Alan Donald Brett, Christopher Brian Hartley Wolstenholme, Philip Gerard Conaghan
The Journal of Rheumatology Apr 2019, jrheum.180541; DOI: 10.3899/jrheum.180541
Precision, Reliability, and Responsiveness of a Novel Automated Quantification Tool for Cartilage Thickness: Data from the Osteoarthritis Initiative
Michael Antony Bowes, Gwenael Alain Guillard, Graham Richard Vincent, Alan Donald Brett, Christopher Brian Hartley Wolstenholme, Philip Gerard Conaghan
The Journal of Rheumatology Apr 2019, jrheum.180541; DOI: 10.3899/jrheum.180541